Clinicopathological characteristics of primary hepatic carcinoma patients
| Characteristics | n | Tumor HBx expression | P value | Tumor CD8 expression | P value | Tumor PD-L1 expression | P value | |||
| Low | High | Low | High | Low | High | |||||
| All patients | 40 (100%) | 15 | 25 | 30 | 10 | 24 | 16 | |||
| Gender | ||||||||||
| Male | 32 (80.0%) | 12 | 20 | 1.000 | 25 | 7 | 0.361 | 18 | 14 | 0.333 |
| Female | 8 (20.0%) | 3 | 5 | 5 | 3 | 6 | 2 | |||
| Age | ||||||||||
| ≤50 | 13 (32.5%) | 4 | 9 | 0.542 | 11 | 2 | 0.330 | 10 | 3 | 0.130 |
| >50 | 27 (67.5%) | 11 | 16 | 19 | 8 | 14 | 13 | |||
| Tumor site | ||||||||||
| Left | 14 (35.0%) | 6 | 8 | 0.608 | 9 | 5 | 0.251 | 8 | 6 | 0.787 |
| Right | 26 (65.0%) | 9 | 17 | 21 | 5 | 16 | 10 | |||
| Tumor size | ||||||||||
| ≤5 cm | 26 (65.0%) | 9 | 17 | 0.608 | 21 | 5 | 0.251 | 14 | 12 | 0.279 |
| >5 cm | 14 (35.0%) | 6 | 8 | 9 | 5 | 10 | 4 | |||
| HBV infection | ||||||||||
| Positive | 25 (62.5%) | 0 | 25 | <0.001 | 25 | 0 | <0.001 | 9 | 16 | <0.001 |
| Negative | 15 (37.5%) | 15 | 0 | 5 | 10 | 15 | 0 | |||
| Pathological type | ||||||||||
| Hepatocellular carcinoma | 36 (90.0%) | 13 | 23 | 0.586 | 28 | 8 | 0.224 | 22 | 14 | 0.667 |
| Non-hepatocellular carcinoma | 4 (10.0%) | 2 | 2 | 2 | 2 | 2 | 2 | |||
| Pathological grading | ||||||||||
| I–II | 37 (92.5%) | 13 | 24 | 0.278 | 27 | 10 | 0.299 | 22 | 15 | 0.806 |
| III | 3 (7.5%) | 2 | 1 | 3 | 0 | 2 | 1 | |||
| TNM stage | ||||||||||
| I–II | 26 (65.0%) | 9 | 17 | 0.608 | 21 | 5 | 0.251 | 14 | 12 | 0.279 |
| III–IV | 14 (35.0%) | 6 | 8 | 9 | 5 | 10 | 4 | |||
The difference between the positive group and the negative group was statistically significant (P<0.001).
HBV, hepatitis B virus; HBx, hepatitis B virus X; PD-L1, programmed death receptor 1 and its ligand 1; TNM, tumor, node, metastases.